<DOC>
	<DOCNO>NCT01367665</DOCNO>
	<brief_summary>This single-arm , open-label , multi-center study evaluate safety efficacy vismodegib ( GDC-0449 ) patient locally advance metastatic basal cell carcinoma . Patients receive oral dos vismodegib 150 mg daily disease progression unacceptable toxicity .</brief_summary>
	<brief_title>STEVIE : A Study Vismodegib Patients With Locally Advanced Metastatic Basal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Metastatic locally advance basal cell carcinoma consider inoperable surgery contraindicate radiotherapy contraindicate inappropriate Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Concurrent antitumor therapy Completion recent antitumor therapy le 21 day prior initiation treatment Uncontrolled medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>